PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL

• Jake Shortt,
• Brian Poligone,
• Vincent Ribrag,
• Pier Luigi Zinzani,
• Dima El-Sharkawi,
• Jan Walewski,
• Anca Prica,
• Laksmi Wilson,
• Sonia Souza,
• Harold Keer,
• Jason Taylor,
• Enrica Marchi

Affiliations

Jake Shortt

1 Monash University and Monash Health, Clayton, Victoria, Australia

Brian Poligone

2 Rochester Skin Lymphoma Medical Group, PLLC, Fairport, United States

Vincent Ribrag

3 Institute of Hematology “Seràgnoli” University of Bologna Italy, Villejuif, France

Pier Luigi Zinzani

4 Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy

Dima El-Sharkawi

5 The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom

Jan Walewski

6 Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warszawa, Poland

Anca Prica

7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Laksmi Wilson

8 Astex Pharmaceuticals, Inc., Pleasanton, United States

Sonia Souza

8 Astex Pharmaceuticals, Inc., Pleasanton, United States

Harold Keer

8 Astex Pharmaceuticals, Inc., Pleasanton, United States

Jason Taylor

8 Astex Pharmaceuticals, Inc., Pleasanton, United States

Enrica Marchi

9 Emily Couric Clinical Cancer Center, University of Virginia, Charlottsville, United States